Suboptimal Cross-linking of Antigen Receptor Induces Syk-dependent Activation of p70S6 Kinase through Protein Kinase C and Phosphoinositol 3-Kinase*

Hsiu-Ling Li, William Davis, and Ellen PuréDagger

From the Wistar Institute, Philadelphia, Pennsylvania 19104

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Ligation of the B cell antigen receptor (BCR) induces a cascade of signaling pathways that lead to clonal expansion, differentiation, or abortive activation-induced apoptosis of B lymphocytes. BCR-mediated cross-linking induces the rapid phosphorylation of protein tyrosine kinases. However, the pathways leading to the activation of downstream serine/threonine kinases such as mitogen-activated protein kinase, p90Rsk, and p70S6 kinase (p70S6k) that mediate reorganization of the actin cytoskeleton, cell cycle progression, gene transcription, and protein synthesis have not been delineated. We recently demonstrated that cross-linking of BCR leads to activation of p70S6k in B lymphocytes. In this report, we demonstrate that multiple protein tyrosine kinase-dependent signal transduction pathways induced by BCR lead to the activation of p70S6k. These distinct pathways exhibit different thresholds with respect to the extent of receptor cross-linking required for their activation. Activation of p70S6k by suboptimal doses of anti-Ig is Syk-dependent and is mediated by protein kinase C and phosphoinositol 3-kinase. Moreover, the activation of p70S6k results in phosphorylation of S6 protein which is important for ribosomal protein synthesis and may be coupled to BCR-induced protein and DNA synthesis in primary murine B cells.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Ligation of the antigen receptor (BCR)1 can lead to clonal expansion, differentiation, or abortive activation-induced apoptosis of B lymphocytes. Several early signaling events induced by ligation of BCR have been described including the rapid activation of protein tyrosine kinases, calcium mobilization, and activation of downstream serine/threonine kinases (1-8). These early events are followed by cytoskeletal reorganization, induced gene expression, and increased mRNA and protein synthesis (9). The relationship between the defined early signal transduction events, intermediate signaling events, and the fate of B cells is not clear.

We have been investigating the protein tyrosine kinase-dependent regulation of BCR-mediated activation of serine/threonine kinases. We demonstrated that ligation of BCR on the avian B cell line DT40 results in activation of mitogen-activated protein kinase (MAPK) and members of two families of ribosomal S6 kinases, p90Rsk and p70S6 kinase (p70S6k) (10). Ribosomal S6 kinases are highly conserved proteins that are critical for translational regulation particularly of genes containing poly-pyrimidine tracts in their 5'-untranslated regions that encode essential components of the protein synthesis apparatus (11-15). These kinases can regulate mRNA translation through phosphorylation of ribosomal S6 protein. Although both p90Rsk and p70S6k can phosphorylate S6 in vitro, p70S6k likely is responsible for in vivo phosphorylation of S6 (16-20).

Several lines of evidence suggest that p70S6k is also involved in cell cycle regulation (18, 21-26). First, microinjection of antibody against p70S6k abolished PDGF-induced cell cycle progression in rat embryo fibroblasts (21-23). Many other studies of the function of p70S6k have relied on selective inhibition by the immunosuppressant drug rapamycin that inactivates p70S6 kinase without affecting mitogen-induced activation of p90Rsk or MAPK (18, 24). Based on inhibition of G1 progression by rapamycin, it has been suggested that p70S6k plays an important role in the growth of hematopoietic cells (18, 24-27). Recent evidence obtained with embryonic stem cells in which p70S6k was depleted by targeted gene disruption supports its role in ribosomal protein synthesis and cell growth (20). Although mitogens that activate p70S6k can simultaneously activate mitogen-activated protein kinases, there is evidence that MAPK and p70S6k lie on discrete pathways (16) and that p70S6k and MAPK may play distinct roles in regulating cell growth (21-23, 28, 29). We recently demonstrated that BCR-mediated activation of p70S6k can occur independently of the pathways that mediate MAPK or p90Rsk (10). However, the role of either MAPK or p70S6k in B cell proliferation has not been determined.

Mitogen-induced activation of p70S6k is initiated by ligand binding to receptor tyrosine kinases in the case of PDGF and insulin stimulation, for example, or through activation of non-receptor tyrosine kinases as in the case of T cell stimulation by IL-2 (30-32). Activation of these protein tyrosine kinases leads to the activation of PI3-kinase-dependent as well as PI3-kinase-independent pathways that lead to the activation of p70S6 kinase (33-37). The activation of protein tyrosine kinases is an essential step in antigen receptor-mediated activation of B cells. Lyn, one of several Src family kinases expressed in B cells, Syk, and Btk are three of the major tyrosine kinases involved in BCR-mediated activation (38-42). The essential role of these tyrosine kinases in the regulation of some early signaling events such as the activation of phospholipase-Cgamma has been established (5, 43, 44). However, the pathways leading to the activation of the serine/threonine kinases such as MAPK, p90Rsk, and p70S6k that may be required for the reorganization of the actin cytoskeleton, cell cycle progression, gene transcription, and protein translation associated with antigen receptor-mediated activation of B lymphocytes have not been delineated. In this report, we define the BCR-mediated protein tyrosine kinase-dependent signaling cascades that lead to activation of p70S6k. We futher demonstrate that the activation of p70S6k results in the phosphorylation of S6 protein that is important for ribosomal protein synthesis and may be coupled to BCR-induced DNA synthesis in primary murine B cells.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Isolation of Primary B Cells-- Splenic B cells were isolated from 6- to 8-week-old CD2F1 mice as described (45). Freshly isolated splenocytes were depleted of red blood cells using hypotonic red blood cell lysis buffer (Sigma). T cells were depleted by antibody (monoclonal anti-CD4 Ab (GK1.5), anti-CD8 Ab (3.168.8), and anti-Thy1.2 Ab (J1j))-dependent complement-mediated cytolysis using Low-Tox® guinea pig sera as a source of complement (Accurate Chemicals). The enrichment of B cells was over 85% as measured by reactivity with anti-B220 and fluorescence-activated flow cytometry. The purified B cells were incubated in serum-free medium for 3 h prior to stimulation.

Fluorescence-activated Flow Cytometry-- Primary B cells and DT40 cells were incubated with FITC-conjugated anti-B220 mAb and mouse anti-chicken IgM mAb (M4), respectively, for 30 min at 4 °C. DT40 cells were then reacted with FITC-conjugated F(ab')2 goat anti-mouse Ab for an additional 30 min at 4 °C. These cells were then subjected to flow cytometric analysis on a FACScan and analyzed using Cell Quest software (Becton Dickinson).

Cell Culture and DNA Transfection-- The chicken B cell line, DT40, and mutant DT40 cells deficient in both Syk and Lyn (DT40Syk-Lyn-) were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 1% chicken serum, 100 µg/ml penicillin, 100 µg/ml streptomycin, and 2 mM glutamine. DT40Lyn- and DT40Syk- cells were cultured in the same medium containing 2 mg/ml G418 (43). Wild-type and an enzymatically inactive mutant of human Syk, SykK402R, were cloned into the expression vector pApuro (10) and transfected into DT40Syk- cells by electroporation using a gene pulser apparatus (Bio-Rad) at 330 V, 250 microfarads and selected in the presence of 0.5 µg/ml puromycin. Puromycin-resistant clones were initially screened by Southern blotting of genomic DNA and further selected for expression of comparable levels of surface immunoglobulin by flow cytometry and for expression of comparable amounts of wild-type Syk or SykK402R based on immunoblotting. All results are representative of at least three experiments using a minimum of two independent clones expressing wild-type Syk or SykK402R.

Immunoprecipitation and Immunoblotting-- For activation of p70S6k, cells in an exponential growth phase were serum-starved for 12 h prior to stimulation. DT40 cells were untreated or treated with rapamycin (Calbiochem) or 0.5 µM staurosporine (Sigma) for 15 min or 3 h, respectively. Cells (2 × 107 cells/ml) were then stimulated with indicated concentrations of mouse anti-chicken IgM mAb M4 or 100 nM phorbol ester (phorbol 12,13-dibutyrate (PdBu), Sigma) for 30 min at 37 °C. Cells were quickly chilled on ice and pelleted by centrifugation immediately after stimulation. Cell pellets were lysed in 400 µl of ice-cold lysis buffer (1× phosphate-buffered saline, 1 mM phenylmethylsulfonyl fluoride, 100 µg/ml soybean trypsin inhibitor, 20 µg/ml aprotinin, 100 µg/ml leupeptin, 1% Nonidet P-40, 0.1% deoxycholate, 10 mM NaF, 10 mM sodium pyrophosphate, and 100 mM sodium orthovanadate) for 15 min on ice. Cell lysates were clarified by centrifugation at 15,000 rpm for 10 min. Clarified cell lysates were normalized based on protein concentration as determined using the BCA® kit (Pierce), and equal amounts of protein were subjected to immunoprecipitation or immunoblotting for each lysate. The post-nuclear extracts (1 mg) were incubated directly with polyclonal anti-p70S6k (Santa Cruz Biotechnology) at 4 °C overnight. Immune complexes were precipitated with 30 µl of protein A-agarose beads (Life Technologies, Inc.) for an additional 3 h incubation at 4 °C. The immune precipitates were washed twice with lysis buffer followed by two washes with phosphate-buffered saline. Bound proteins were eluted by boiling in Laemmli buffer containing 0.4% dithiothreitol and resolved on 8% SDS-polyacrylamide gel electrophoresis (National Diagnostics Inc.). Proteins less than 45 kDa were run off gels to obtain better resolution of the hypophosphorylated and hyperphosphorylated forms of the proteins of interest and to maximize separation from the antibody used for immunoprecipitation. The proteins were transferred to polyvinylidene difluoride membrane and subjected to immunoblotting. The blots were blocked with TNB buffer (30 mM Tris, pH 7.6, 75 mM NaCl, 3% bovine serum albumin) overnight at 4 °C. The blots were then incubated with polyclonal anti-p7056k Ab followed by 1 µCi/ml iodinated protein A for 45 min at room temperature followed by autoradiography.

For detection of in vivo phosphorylation of endogenous S6 protein, 100 µg of cell lysates were resolved on 10% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes as described above. Membranes were immunoblotted with a polyclonal antibody against the phosphorylated S6 protein (a generous gift from Dr. Morris Birnbaum, University of Pennsylvania) followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit Ig. Reactivity was detected using an ECL kit (Amersham Pharmacia Biotech).

In Vitro Kinase Assays-- Anti-p70S6k immunoprecipitates were prepared as described above and washed once with kinase buffer (50 mM MOPS, pH 7.2, 1 mM dithiothreitol, 30 µM ATP, 5 mM MgCl2). The immune complexes were then resuspended in 12.5 µl of kinase buffer containing 0.3 mg/ml S6 peptide (Santa Cruz Biotechnology) and 5 µCi of [32P-gamma ]ATP (6000 Ci/mmol) and incubated at 30 °C for 15 min. The reactions were terminated by boiling in 7.5 µl of 3× Laemmli buffer for 5 min. Samples were resolved on an 18.5% polyacrylamide gel which was dried and subjected to autoradiography.

Quantitation of DNA Synthesis-- Splenic B cells (1 × 106 cells/ml) were incubated with the indicated dose of rapamycin 15 min prior to and throughout the stimulation period. Cells (200 µl) were cultured in 96-well microtiter plates and stimulated with the indicated concentrations of F(ab')2 goat anti-mouse IgM in the presence or absence of baculovirus-derived murine IL-4 and soluble recombinant CD40 ligand (CD40L)/CD8 fusion protein (a generous gift from Dr. Jan Erikson, Wistar Institute) for 48 h. Cells were pulsed with 1 µCi of [3H]thymidine per well during the final 12 h of stimulation. [3H]Thymidine incorporation was measured using a Harvester 96® (Tomtec, OR) and analyzed using Matrix 96 software (Packard).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

BCR-induced Activation of p70S6k in Splenic B Cells Is Transient and Dose-dependent-- Activation of p70S6k has been implicated in the regulation of several pivotal functions including translation, transcription, and cell growth in several cell types in response to growth factor (e.g. PDGF), cytokine (e.g. interleukin 2), or hormone (e.g. insulin) stimulation (24, 37, 46-50). However, the role of p70S6k in antigen receptor-mediated signaling is not known. We previously demonstrated that ligation of BCR can induce activation of p70S6k in the DT40 avian B cell line (10). In this study, we extended this finding to primary splenic B cells and found that engagement of BCR can lead to activation of p70S6k as measured by shift in mobility of p70S6k on SDS-polyacrylamide gel electrophoresis and in vitro kinase assays. Ligation of BCR with an optimal dose of anti-Ig induced maximal phosphorylation and activation of p70S6k in primary splenic B cells at 30 min after stimulation (Fig. 1A). The BCR-mediated activation of p70S6k decreased to basal levels at 2 h after stimulation. The phosphorylation of p70S6k was also dependent on the dose of anti-Ig (Fig. 1B). Importantly, in vivo phosphorylation of S6 protein was also induced in a dose-dependent manner (Fig. 1B). Together these data indicate that the degree to which p70S6k is activated is determined by the extent of receptor cross-linking.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 1.   Activation of p70S6k following BCR cross-linking in primary B cells is transient and dose-dependent. A, the kinetics of BCR-induced activation of p70S6k. Splenic B cells were isolated and stimulated with 10 µg/ml F(ab')2 goat anti-mouse IgM Ab for the indicated times. Equal amounts of cell lysates (500 µg) were immunoprecipitated with anti-p70S6k Ab. Half of the immune complexes were immunoblotted with anti-p70S6k Ab to measure the mobility shift of p70S6k (top panel). The second half of the immune complexes were subjected to an in vitro kinase assay using S6 peptide as an exogenous substrate (bottom panel). These data represent at least four independent experiments. B, dose-dependent anti-Ig-induced activation of p70S6k. Splenic B cells were stimulated with the indicated doses of anti-Ig for 30 min. The mobility shift of p70S6k was measured as described in A (top panel). For in vivo phosphorylation of S6 protein, equal amounts of cell lysates were immunoblotted with anti-phospho-S6 protein Ab (bottom panel).

Activation of p70S6k Is Rapamycin-sensitive and Associated with BCR-induced Phosphorylation of S6 Protein and DNA Synthesis-- The immunosuppressive drug rapamycin selectively inhibits growth factor and IL-2-induced activation of p70S6k in fibroblasts and T cells, respectively (15, 18, 24, 51-54). Inhibition of p70S6k by rapamycin also correlated with the inhibition of cell cycle progression of fibroblasts and T cells stimulated by mitogens (27, 49, 54) and the in vivo phosphorylation of S6 protein (20). Furthermore, targeted disruption of p70S6k established that p70S6k is required for in vivo phosphorylation of S6 protein in embryonic stem cells (20). To investigate the role of p70S6k in downstream responses in B cells we examined the dose dependence and rapamycin sensitivity of anti-Ig-induced activation of p70S6k, S6 phosphorylation, and DNA synthesis.

As expected, anti-Ig induced DNA synthesis in a dose-dependent fashion (Fig. 2A). Interestingly, the dose responses of anti-Ig-induced activation of p70S6k (Fig. 1B), DNA synthesis (Fig. 2A), and S6 phosphorylation (Fig. 1B) were all similar. BCR-mediated activation of p70S6k and in vivo S6 phosphorylation was inhibited by rapamycin (Fig. 2B). Furthermore, the inhibition of p70S6k by rapamycin correlated with the dose-dependent inhibition of BCR-mediated DNA synthesis by rapamycin (Fig. 2A). The inhibition by rapamycin was not due to cytotoxicity since the BCR-mediated activation of p90Rsk was not affected (data not shown). Moreover, stimulation of rapamycin-treated B cells with IL-4 and CD40L rescued DNA synthesis in rapamycin-treated anti-Ig-stimulated B cells (Fig. 2C). The effect of CD40L and IL-4 was not due to inactivation of rapamycin since BCR-mediated activation and phosphorylation of p70S6k were inhibited by rapamycin even in the presence of IL-4 and CD40L (data not shown). Taken together, these results indicated that BCR-mediated activation of p70S6k leads to the phosphorylation of endogenous S6 protein and may contribute to enhanced DNA synthesis in B cells. In addition, IL-4 and CD40L may synergize with BCR by inducing alternate signaling pathway(s) that are resistant to rapamycin and therefore do not require p70S6k but lead to DNA synthesis.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Rapamycin inhibits BCR-induced p70S6k activation and DNA synthesis. A, DNA synthesis. Splenic B cells were incubated with the indicated doses of rapamycin for 15 min prior to and during stimulation. Cells were then cultured in the presence or absence of various doses of F(ab')2 goat anti-mouse IgM Ab for 48 h; 1 µCi of [3H]thymidine was added for the last 12 h of the incubation period. The amounts of incorporated [3H]thymidine were measured, and the results are presented as the average ± S.E. of triplicates for each condition. These data are representative of at least three independent experiments. B, mobility shift of p70S6k and in vivo phosphorylation of S6 protein. B cells were pretreated with rapamycin for 15 min and stimulated with 10 µg/ml F(ab')2 goat anti-mouse IgM Ab in the presence of rapamycin for an additional 30 min. For mobility shift of p70S6k, equal amounts of cell lysates were immunoprecipitated followed by immunoblotting with anti-p70S6k Ab. For in vivo phosphorylation of S6 protein, equal amounts of cell lysates were immunoblotted with anti-phospho-S6 protein. C, IL-4 and CD40 ligand rescue the inhibition of BCR-mediated DNA synthesis by rapamycin. Rapamycin pretreated B cells were stimulated with 50 µg/ml F(ab')2 goat anti-mouse IgM Ab in the presence or absence of IL-4 and CD40L for 36 h and then pulsed with [3H]thymidine for 12 h, and the amount of incorporated [3H]thymidine was measured. The results are presented as percent of inhibition of DNA synthesis by rapamycin in anti-Ig-stimulated cells as compared with that in stimulated cells without rapamycin. All data are representative of at least three independent experiments.

Syk and Lyn Mediate Activation of p70S6k following Suboptimal Cross-linking of the BCR-- Mitogen-induced activation of p70S6 kinase in other cell types is mediated either by receptor tyrosine kinases (e.g. insulin receptor and PDGF receptor) or through cytoplasmic tyrosine kinases (IL-2 receptor). In addition, the activation of cytoplasmic tyrosine kinases is critical for antigen receptor-mediated B cell activation (1-8). Therefore, in an effort to define BCR-coupled signaling pathways that lead to the activation of p70S6 kinase, we first investigated the role of tyrosine kinases.

Treatment with genistein, a tyrosine kinase inhibitor, blocked both basal and anti-Ig-induced hyperphosphorylation of p70S6k in primary B cells and DT40 B cells (Fig. 3A). These data suggest that both basal and BCR-mediated activation of p70S6k is dependent on upstream tyrosine kinases. To define the role of Syk and Lyn we compared the activation of p70S6k in DT40 cells deficient in either Syk or Lyn to that in parental DT40 cells. We previously reported that the activation of p70S6k was comparable in DT40Syk-, DT40Lyn-, and parental DT40 cells following stimulation with an optimal dose of anti-Ig (10). These results suggested either that Lyn and Syk were each sufficient to mediate BCR-induced activation of p70S6k in DT40 cells or that neither of these tyrosine kinases were required at least following optimal B cell receptor cross-linking. We have addressed the role of Syk and Lyn further by comparing the activation of p70S6k in DT40 cells deficient in both Syk and Lyn (DT40Syk-Lyn-) and by examining whether Syk or Lyn plays an important role in the activation of p70S6k following stimulation with suboptimal doses of anti-Ig that induce a degree of receptor cross-linking more likely consistent with stimulation by antigen.


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 3.   A, tyrosine kinases are required for both basal and anti-Ig-induced phosphorylation of p70S6k. Splenic B cells (left panel) and DT40 B cells (right panel) were pretreated with 50 µg/ml genistein for 30 min prior to stimulation with 10 µg/ml F(ab')2 goat anti-mouse IgM and mouse anti-chicken IgM for 30 min, respectively. Equal amounts of cell lysates (500 µg) were immunoprecipitated and immunoblotted with anti-p70S6k Ab. B, the requirement for Syk and Lyn for activation of p70S6k are dependent on the extent of receptor cross-linking. Parental and mutant DT40 cells were stimulated with the indicated doses of mouse anti-chicken IgM Ab (M4) for 30 min. Equal amounts of cell lysates were immunoprecipitated with anti- p70S6k Ab. The immune complexes were divided for immunoblotting with anti-p70S6k Ab (top panel) and for in vitro kinase assays (bottom panel). C, parental DT40 and mutant DT40 cells express comparable amounts of B cell receptors. DT40 cells and mutant DT40 cells were incubated with mouse anti-chicken IgM mAb M4 at 4 °C for 30 min followed by staining with FITC-conjugated F(ab')2 goat anti-mouse IgG at 4 °C for 30 min. Cells were analyzed by flow cytometry. D and E, Syk is required for BCR-induced activation of p70S6k in response to low dose anti-Ig. DT40 cells were stimulated with indicated doses of M4 Ab at 37 °C for 30 min. Equal amounts of cell lysates were immunoprecipitated with anti-p70S6k Ab. The immune complexes were immunoblotted with anti-p70S6k Ab (D) or subjected to in vitro kinase assays (E, top panel). The results of the kinase assays were quantitated using a PhosphorImager and ImageQuant software (Molecular Dynamics) and expressed as arbitrary PhosphorImager units (E, bottom panel).

The basal phosphorylation of p70S6k in DT40Syk-Lyn- cells was decreased compared with that in parental cells (Fig. 3B). Thus, Syk and Lyn appear to be involved in the regulation of basal phosphorylation of p70S6k. Furthermore, compared with the activation of p70S6k seen in parental DT40 cells, activation of p70S6k was abolished in DT40Syk-Lyn- cells following stimulation with low doses of anti-Ig (~1-3 µg/ml mAb M4) (Fig. 3B). This phenotype is not due to lower levels of BCR expression in DT40Syk-Lyn- cells compared with that in parental cells since DT40Syk-Lyn- cells express comparable amounts of BCR to that in parental DT40 cells by FACS analysis (Fig. 3C). These data suggest Syk or Lyn are required for activation of p70S6 kinase in response to suboptimal cross-linking of the BCR but that optimal doses of anti-Ig (100 µg/ml mAb M4) promote sufficient cross-linking of BCR to initiate alternate pathway(s) with higher threshold(s) of activation that also lead to albeit reduced activation of p70S6 kinase independent of both Syk and Lyn.

To investigate further the roles of Syk and Lyn, we compared anti-Ig-induced phosphorylation/activation of p70S6k in DT40, DT40Syk-, DT40Lyn-, and DT40Syk-Lyn- cells in response to stimulation by different doses of anti-Ig. In response to low dose of anti-Ig (1 µg/ml mAb M4), BCR-induced activation of p70S6k was comparable in DT40Lyn- but ablated in DT40Syk- and DT40Syk-Lyn- cells compared with that in DT40 cells (Fig. 3D, top panel, and E). Interestingly, the fold stimulation over basal activity of p70S6k in DT40Lyn- cells is higher than that in DT40 cells in response to BCR cross-linking as a result of a decrease in the basal activity of p70S6k in the mutant DT40 cells compared with parental DT40 cells (Fig. 3E). In response to increasing concentrations of anti-Ig, suboptimal activation of p70S6k was evident starting at 3 µg/ml M4 in DT40Syk- cells but reduced compared with parental cells, whereas DT40Syk-Lyn- cells were unresponsive to this intermediate dose (Fig. 3D, middle panel). Thus, the dose response of Syk-deficient cells is shifted compared with parental DT40 cells and Lyn-deficient DT40 cells indicating that BCR-induced activation of p70S6 kinase is primarily mediated by a Syk-dependent pathway at low doses of anti-Ig cross-linking. The more marked shift in the dose response of DT40Syk-Lyn- cells compared with DT40Syk- cells indicates that Lyn can also mediate BCR-induced activation of p70S6 kinase in the absence of Syk. Taken together, these data demonstrate that Syk is required for activation of p70S6 kinase and that Lyn can also contribute to its activation in response to suboptimal cross-linking of BCR but at higher doses of anti-Ig (>10 µg/ml M4) a threshold of BCR cross-linking in DT40 cells is reached that leads to the activation of p70S6 kinase via an alternative pathway(s) that does not require either Syk or Lyn (Fig. 3, B and D, bottom panel, and E).

Enzymatic Activity of Syk Is Required for BCR-mediated Activation of p70S6 Kinase-- To test whether the failure of low dose anti-Ig to result in activation of p70S6k in DT40Syk- cells was due to the absence of Syk, we determined if expression of human Syk could revert the phenotype to that of parental DT40 cells. DT40Syk- cells were transfected with wild-type human Syk and an enzymatically inactive mutant K402R (10). Stable transfectants were established and selected based on expression of comparable levels of Syk and membrane immunoglobulin by immunoblotting and flow cytometry analysis, respectively. Expression of wild-type human Syk in DT40Syk- cells reverted both basal and suboptimal anti-Ig-induced activation of p70S6 kinase to the parental phenotype, whereas expression of the catalytically inactive mutant, K402R, did not (Fig. 4). Thus the defect in DT40Syk- cells can be attributed to the loss of Syk. Furthermore, the enzymatic activity of Syk is required for the BCR-induced activation of p70S6k in response to low doses of anti-Ig cross-linking.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   The catalytic activity of Syk is required for BCR-mediated activation of p70S6k. DT40Syk- cells stably transfected with wild-type human Syk cDNA or a catalytically inactive mutant form of Syk, SykK402R, were stimulated with 2 µg/ml M4 Ab for 30 min. Equal amounts of cell lysates were immunoprecipitated with anti-p70S6k Ab. The immune complexes were divided for immunoblotting with anti-p70S6k Ab (top panel) and an in vitro kinase assay using S6 peptide as a substrate (bottom panel).

BCR-mediated Activation of p70S6 Kinase Can Occur via Both PKC-dependent and -independent Pathways-- We next sought to define the downstream effector molecules that can mediate the Syk-dependent activation of p70S6 kinase. PI3-kinase and protein kinase C (PKC) have both been implicated upstream of p70S6k in growth factor and cytokine-induced signaling (35-37, 46, 55). Syk was previously shown to be required for anti-Ig-induced activation of phospholipase-Cgamma and thereby generation of phosphoinositide triphosphate and diacylglycerol followed by Ca2+ mobilization. Both diacylglycerol and Ca2+ are involved in activation of several PKC isoforms, conventional PKC, and novel PKC (56). We therefore tested the hypothesis that PKC transduces the signals from Syk to p70S6k in B cells in response to low dose anti-Ig cross-linking. To determine the role of PKC in the Syk-dependent activation of p70S6 kinase, we tested the effect of PKC inhibition either by treatment with a PKC inhibitor, staurosporine, or by chronic treatment with PdBu on the response of DT40 and DT40Lyn- cells stimulated with low dose anti-Ig. Consistent with our previous report, short term treatment with phorbol ester, PdBu (10), or low dose anti-Ig induced optimal activation of p70S6k in both DT40 and DT40Lyn- cells (Fig. 5A). Inhibition of PKC by staurosporine resulted in a complete abrogation of p70S6k in both DT40 and DT40Lyn- cells in response to PdBu or anti-Ig stimulation (Fig. 5A). To define further the role of specific PKC isoforms in BCR-mediated activation of p70S6k, we also measured the effects of chronic treatment with PdBu on p70S6k activation. In contrast to short term treatment with phorbol esters (56), prolonged treatment with phorbol esters induces ubiquitination and proteolytic degradation of phorbol ester responsive PKC isoforms (57). Interestingly, the BCR-induced activation of p70S6k was also completely abolished in PKC-depleted DT40 cells but was only partially inhibited in DT40Lyn- cells (Fig. 5B, compare lanes marked by asterisks). The partial inhibition in DT40Lyn- was not due to residual PdBu-sensitive PKC since these cells were unresponsive to restimulation of PdBu (Fig. 5B). The effect of pre-exposure to PdBu was not due to cytotoxicity since BCR-induced tyrosine phosphorylation was unaffected by PKC depletion (Fig. 5C). These data suggest that Syk-dependent activation of p70S6k requires PKC in both DT40 and DT40Lyn- cells. Moreover, phorbol ester-responsive PKC isoforms, in particular, are essential for anti-Ig-induced activation of p70S6k in DT40 cells but not in DT40Lyn- cells. These data also suggested that non-PdBu-sensitive PKC isoforms might be hyperactivated and sufficient for the partial activation of p70S6k in DT40Lyn- cells depleted of PdBu-sensitive PKC isoforms.


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 5.   Protein kinase C is involved in anti-Ig-induced activation of p70S6k. A, cells were treated with 0.5 µM staurosporine for 3 h prior to stimulation. Cells were then stimulated with 2 µg/ml M4 Ab for 30 min. The phosphorylation states of p70S6k were determined by mobility shift as described in Fig. 4. B, cells were cultured in serum-free media in the presence or absence of 5 µM PdBu for 12 h before stimulation with anti-Ig. The PKC-depleted cells were then stimulated with 2 µg/ml M4 or 50 nM PdBu at 37 °C for 30 min. The phosphorylation states of p70S6k were compared by mobility shift as described above. C, the same PKC-depleted cells were stimulated with 2 µg/ml M4 at 37 °C for 3 min. Equal amounts of cell lysates (50 µg) were immunoblotted with anti-phosphotyrosine Ab.

Role of PI3-kinase in BCR-mediated Activation of p70S6k-- PI3-kinase has been implicated in activation of p70S6k (26, 31, 36, 37, 55). In addition, several non-PdBu-sensitive PKC isoforms were shown to be activated by PI3-kinase. PI3-kinase was therefore also a likely candidate as a mediator of low dose anti-Ig-induced activation of p70S6 kinase in DT40Lyn- cells (26, 31, 36, 37, 55). To address the role of PI3-kinase, we tested the sensitivity of anti-Ig-induced activation of p70S6 kinase to the selective inhibitors of PI3-kinase, wortmannin, and Ly294002. We found that both basal and low dose anti-Ig-induced activation of p70S6k in DT40 and DT40Lyn- cells were partially sensitive to 50 nM wortmannin and 4 µM Ly294002 with the response in DT40Lyn- cells being somewhat more sensitive (Fig. 6, A and B). Furthermore, treatment of PKC-depleted DT40Lyn- cells with Ly294002 completely abrogated anti-Ig-induced activation of p70S6k (Fig. 6C). Thus, together, PKC and PI3-kinase account for the transduction of the Syk-dependent activation of p70S6k in DT40 and DT40Lyn- cells. The partial inhibition of p70S6k activation by wortmannin and Ly294002 was not likely due to incomplete inhibition of PI3-kinase since the BCR-induced activation of Akt, another downstream effector of PI3-kinase, was completely ablated under these conditions.2 Furthermore, BCR-induced activation of p90Rsk was not affected demonstrating the specificity and lack of toxicity of the inhibitors (data not shown). Taken together, these data demonstrate that, in addition to PKC, a PI3-kinase-dependent pathway can also mediate Syk-dependent activation of p70S6k in DT40 and DT40Lyn- cells. However, the PI3-kinase pathway does not appear to be sufficient for the activation of p70S6k in parental DT40 cells in the absence of phorbol ester-sensitive PKC isoforms, whereas this pathway can be sufficiently activated to mediate activation of p70S6 kinase in Lyn-deficient cells under the same condition.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 6.   The role of PI3-kinase in BCR-mediated activation of p70S6k. Cells were treated with 50 nM wortmannin (A) or 4 µM Ly294002 (B, bottom panel) for 15 min prior to stimulation with 2 µg/ml mouse anti-chicken IgM Ab (M4) for 30 min. Equal amounts of cell lysates were immunoprecipitated with anti-p70S6k Ab. The immune complexes were divided for immunoblotting with anti-p70S6k Ab (top panel) and in vitro kinase assays (bottom panel) using S6 peptides as exogenous substrates. C, DT40Lyn- cells were treated with PdBu for 12 h followed by incubation with 4 µM Ly294002 for an additional 15 min prior to stimulation. Cells were stimulated with 2 µg/ml M4 or 50 nM PdBu for 30 min. The phosphorylation states of p70S6k were determined as described in Fig. 4.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Antigen receptor-mediated signaling plays a pivotal role in determining the fate of lymphocytes. BCR-mediated cellular responses are based on the nature of the ligand and depend on the integration of additional signals provided, for example by CD40/CD40L-mediated interactions with T cells and T cell-derived cytokines such as IL-4. The state of B cell maturation as well as the dose and nature (e.g. valency, affinity) of the ligand-receptor interaction determine the degree to which receptor-coupled signal transduction pathways are activated. In a primary immune response, unprimed B cells can be stimulated even by limiting concentrations of nominal antigen and undergo clonal expansion and affinity maturation. In contrast, ligand binding to immature autoreactive B cells typically results in clonal deletion or anergy. Although anergic self-reactive B cells in the periphery are non-responsive to low doses of antigen, high receptor occupancy and appropriate T cell help can break tolerance in autoreactive B cells (58, 59). Thus, defining the mechanisms underlying B cell activation in response to varying degrees of receptor engagement is important in understanding B cell activation and tolerance.

We recently demonstrated that ligation of BCR on the avian B cell line DT40 results in activation of MAPK and members of two families of ribosomal S6 kinases, p90Rsk and p70S6k (10). In this report, we extended our previous findings by demonstrating that ligation of BCR can induce activation of p70S6k in murine splenic B cells. BCR-induced activation of p70S6k in primary murine B cells was associated with the in vivo phosphorylation of endogenous S6 protein, which is important for ribosomal biogenesis, and the induction of DNA synthesis. BCR-induced activation of p70S6k was mediated by multiple pathways, but the degree to which the receptor must be cross-linked to activate these pathways, is apparently distinct. Thus, Syk was required for BCR-mediated activation of p70S6k in response to stimulation with low dose anti-Ig. However, as we reported earlier (10) activation of p70S6k in response to high dose anti-Ig was not Syk-dependent, indicating that under optimal stimulatory conditions other pathways can compensate for the absence of Syk. Finally, we demonstrated that Syk-dependent activation of p70S6k is mediated by signal transduction pathway(s) involving PKC and PI3-kinase.

Multiple hierarchical phosphorylation events are involved in the regulation of p70S6k (60-64). At least eight different phosphorylation sites have been implicated; of these, Thr-229, Ser-371, and Thr-389 are essential for p70S6k activation (52, 65-67). Ser-411, Thr-421, and Ser-424 lie in the pseudosubstrate domain and are sensitive to rapamycin treatment (55, 68). Phosphorylation of these three sites appears to occur first and facilitates phosphorylation of Thr-389 via a PI3-kinase-dependent pathway (55). This renders Thr-229 accessible for phosphorylation by the recently identified kinase, PDK1 (49, 55, 60, 69-72). Under appropriate conditions p70S6 kinase can also be activated via a PI3-kinase-independent pathway(s) through PKC, Raf-1, and small G proteins such as Rac1 and Cdc42 (10, 33, 34). In this study, we showed that both PKC and PI3-kinase pathways contribute to the BCR-mediated activation of p70S6k. However it is not yet clear whether these pathways act in parallel or sequentially to activate p70S6k.

The role of p70S6k in B cell activation is not yet clear. However, the similar dose-response curves and rapamycin sensitivity observed for anti-Ig-induced activation of p70S6k, the in vivo phosphorylation of endogenous S6 protein, and induction of DNA synthesis in primary murine B cells suggest that p70S6k may play an important role in BCR-induced protein synthesis and DNA synthesis in B cells. Rapamycin inhibits cell cycle progression in many cell types by binding to its cellular receptor, FK506-binding protein. This complex then associates with the direct target of rapamycin (mTOR·FRAP·RAFT) and inhibits activation of several downstream effectors, including the transcription factor CREM, the translation initiation factor 4E-BP1, cyclin-dependent kinase, and p70S6k (13, 46, 73-75). Thus, the effect of rapamycin on p70S6k is indirect. Additionally, rapamycin also targets other signaling pathways that do not involve p70S6k. Therefore, inhibition of S6 phosphorylation and DNA synthesis by rapamycin does not provide definitive evidence of a role for p70S6k in BCR-induced protein synthesis or cell cycle regulation. Kawasome et al. (20) recently generated p70S6k-deficient embryonic stem cells by targeted gene disruption. The mitogen-induced proliferation of these mutant cells remained partially sensitive to rapamycin. However, the absence of p70S6k in embryonic stem cells resulted in decreased proliferation in response to growth factor stimulation, directly indicating the role of p70S6k in cell cycle progression. Furthermore, ribosomal S6 phosphorylation was ablated in the mutant cells, and translation of mRNA encoding ribosomal proteins was not increased in response to serum indicating that p70S6k plays a unique role in ribosomal protein synthesis. The generation of p70S6k-deficient mice in the future should provide further insight into the role of p70S6k in BCR-induced protein and DNA synthesis as well.

We demonstrated that Syk is required for activation of MAPK even in response to high doses of anti-Ig (10) and as demonstrated in this study, for low dose anti-Ig induced activation of p70S6k. These data suggest that Syk may be essential for antigen-induced clonal expansion of B cells when challenged with physiologic doses of ligand. Consistent with this hypothesis, the differentiation of B-lineage cells in Syk-deficient mice exhibits a block at the pro-B to pre-B transition due to defects in signaling through the pre-B cell receptor that prevent clonal expansion and maturation of pre-B cells (39, 77). In contrast to low dose anti-Ig stimulation, another protein tyrosine kinase-dependent signaling pathway that is inhibited by genistein, but that does not require either Syk or Lyn, can apparently be engaged in p70S6k activation following optimal receptor cross-linking and lead to activation of p70S6k. One likely candidate upstream protein tyrosine kinase that may mediate activation of this alternative pathway is Btk which can activate phospholipase-Cgamma and hence PKC (5).

Other signaling pathways have also been implicated in BCR-induced proliferation responses, in particular the Ras/Mek/MAPK/p90Rsk pathway. However, it is noteworthy that BCR ligation in anergized B cells induced activation of MAPK/p90Rsk but failed to induce proliferation suggesting that this pathway is not sufficient for BCR-induced proliferation (76). If a p70S6k-dependent pathway(s) is primarily responsible, or is required in addition to activation of MAPK to promote BCR-induced growth, then down-regulation of p70S6k is a potential mechanism underlying the unresponsiveness of anergic B cells. Theoretically, regulation of BCR-mediated signaling in anergic cells may be achieved by several mechanisms including uncoupling of the receptor from downstream signaling cascades, down-regulation of receptor expression, or increased activity of negative regulatory mechanisms. With regard to the pathways described in this study, low doses of autoantigen may fail to engage the Syk/Lyn-dependent signaling pathway leading to p70S6k activation. Interestingly, autoreactive B cells in both anti-HEL and anti-DNA Ig transgenic mice express reduced levels of surface Ig (78, 79) and conceivably the threshold doses of antigen may be greater to activate the Syk/Lyn-mediated pathway of p70S6k. Alternatively, the pathway could be completely inactivated in anergic B cells, but at high doses of autoantigen the requirement for this pathway may be overcome by activation of the Syk/Lyn-independent pathway which we demonstrated could also be activated in normal B cells following optimal receptor cross-linking. Although further studies will be required to determine the mechanism(s) underlying the unresponsiveness of anergic B cells, it is interesting to note that the phosphorylation of Syk in response to optimal doses of anti-Ig is defective in anergic B cells (79).

In summary, our results suggest that the activation of p70S6k may be an important intermediate step in antigen receptor-induced activation of B lymphocytes. Future studies will therefore be focused on the role of p70S6k and its regulation in determining the fate of mature B cells challenged by foreign antigen as well as the fate of antigen-challenged autoreactive B cells.

    ACKNOWLEDGEMENTS

We thank Dr. Morris Birnbaum for the generous gift of anti-phospho-S6 protein antisera. We are grateful to Drs. Paul Stein, Margaret M. Chou, and Jan Erikson for many helpful discussions and for reading the manuscript.

    FOOTNOTES

* This study was supported by U. S. Public Health Service Grant AI25185 from the National Institutes of Health (to E. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom all correspondence should be addressed: the Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104-4268.

2 H.-L. Li, W. Davis, and E. Puré, submitted for publication.

    ABBREVIATIONS

The abbreviations used are: BCR, B cell receptor for antigen; mIg, membrane immunoglobulin; p70S6k, p70S6 kinase; PKC, protein kinase C; PI3-kinase, phosphoinositol 3-kinase; MAPK, mitogen-activated protein kinase; PdBu, phorbol 12,13-dibutyrate; PDGF, platelet-derived growth factor; FITC, fluorescein isothiocyanate; Ab, antibody; mAb, monoclonal antibody; MOPS, 4-morpholinepropanesulfonic acid; IL, interleukin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Igarashi, H., Kuwahara, K., Nomura, J., Matsuda, A., Kikuchi, K., Inui, S., and Sakaguchi, N. (1994) J. Immunol. 153, 2381-2393[Abstract/Free Full Text]
  2. Li, T., Tsukada, S., Satterthwaite, A., Havlik, M. H., Park, H., Takatsu, K., and Witte, O. N. (1995) Immunity 2, 451-460[Medline] [Order article via Infotrieve]
  3. Johnson, S. A., Pleiman, C. M., Pao, L., Schneringer, J., Hippen, K., and Cambier, J. C. (1995) J. Immunol. 155, 4596-4603[Abstract]
  4. Panchamoorthy, G., Fukazawa, T., Miyake, S., Soltoff, S., Reedquist, K., Druker, B., Shoelson, S., Cantley, L., and Band, H. (1996) J. Biol. Chem. 271, 3187-3194[Abstract/Free Full Text]
  5. Takata, M., and Kurosaki, T. (1996) J. Exp. Med. 184, 31-40[Abstract]
  6. Jugloff, L. S., and Jongstra-Bilen, J. (1997) J. Immunol. 159, 1096-1106[Abstract]
  7. Lin, J., Tao, J., Dyer, R. B., Herzog, N. K., and Justement, L. B. (1997) J. Immunol. 159, 4823-4833[Abstract]
  8. Ota, Y., and Samelson, L. E. (1997) Science 276, 418-420[Abstract/Free Full Text]
  9. Cox, D., Chang, P., Kurosaki, T., and Greenberg, S. (1996) J. Biol. Chem. 271, 16597-16602[Abstract/Free Full Text]
  10. Li, H.-L., Forman, M. S., Kurosaki, T., and Puré, E. (1997) J. Biol. Chem. 272, 18200-18208[Abstract/Free Full Text]
  11. Jefferies, H. B., Reinhard, C., Kozma, S. C., and Thomas, G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4441-4445[Abstract]
  12. Hershey, J. W. (1989) J. Biol. Chem. 264, 20823-20836[Free Full Text]
  13. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1432-1437[Abstract/Free Full Text]
  14. Watson, K. L., Chou, M. M., Blenis, J., Gelbart, W. M., and Erikson, R. L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13694-13698[Abstract/Free Full Text]
  15. Stewart, M. J., Berry, C. O., Zilberman, F., Thomas, G., and Kozma, S. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10791-10796[Abstract/Free Full Text]
  16. Ballou, L. M., Luther, H., and Thomas, G. (1991) Nature 349, 348-350[CrossRef][Medline] [Order article via Infotrieve]
  17. Moss, M. L., Jin, S.-L. C., Milla, M. E., Burkhart, W., Carter, H. L., Chen, W.-J., Clan, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., Kost, T. A., Lambert, M. H., Leesnitzer, M. A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., Pahel, G., Rocque, W., Overton, L. K., Schoenen, F., Seaton, T., Su, J.-L., Warner, J., Willard, D., and Becherer, J. D. (1997) Nature 385, 733-736[CrossRef][Medline] [Order article via Infotrieve]
  18. Kuo, C. J., Chung, J., Fiorentino, D. F., Flanagan, W. M., Blenis, J., and Crabtree, G. R. (1992) Nature 358, 70-73[CrossRef][Medline] [Order article via Infotrieve]
  19. Terada, N., Lucas, J. J., Szepesi, A., Franklin, R. A., Takase, K., and Gelfand, E. W. (1992) Biochem. Biophys. Res. Commun. 186, 1315-1321[Medline] [Order article via Infotrieve]
  20. Kawasome, H., Papst, P., Webb, S., Keller, G. M., Johnson, G. L., Gelfand, E. W., and Terada, N. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5033-5038[Abstract/Free Full Text]
  21. Lane, H. A., Fernandez, A., Lamb, N. J., and Thomas, G. (1993) Nature 363, 170-172[CrossRef][Medline] [Order article via Infotrieve]
  22. Edelmann, H. M., Kuhne, C., Petritsch, C., and Ballou, L. M. (1996) J. Biol. Chem. 271, 963-971[Abstract/Free Full Text]
  23. Reinhard, C., Fernandez, A., Lamb, N. J. C., and Thomas, G. (1994) EMBO J. 13, 1557-1565[Abstract]
  24. Calvo, V., Crews, C. M., Vik, T. A., and Bierer, B. E. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7571-7575[Abstract]
  25. Aagard-Tillery, K. M., and Jelinek, D. F. (1994) Cell Immunol. 156, 493-507[CrossRef][Medline] [Order article via Infotrieve]
  26. Chou, M. M., and Blenis, J. (1995) Curr. Opin. Cell Biol. 7, 806-814[CrossRef][Medline] [Order article via Infotrieve]
  27. Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M. H., Massague, J., Crabtree, G. R., and Roberts, J. M. (1994) Nature 372, 570-573[Medline] [Order article via Infotrieve]
  28. Seger, R., Biener, Y., Feinstein, R., Hanoch, T., Gazit, A., and Zick, Y. (1995) J. Biol. Chem. 270, 28325-28330[Abstract/Free Full Text]
  29. Papkoff, J., Chen, R.-H., Blenis, J., and Forsman, J. (1994) Mol. Cell. Biol. 14, 463-472[Abstract]
  30. Valius, M., and Kazlauskas, A. (1993) Cell 73, 321-334[Medline] [Order article via Infotrieve]
  31. Chen, R.-H., Chung, J., and Blenis, J. (1991) Mol. Cell. Biol. 11, 1861-1867[Medline] [Order article via Infotrieve]
  32. Mukhopadhyay, N. K., Price, D. J., Kyriakis, J. M., Pelech, S., Sanghera, J., and Avruch, J. (1992) J. Biol. Chem. 267, 3325-3335[Abstract/Free Full Text]
  33. Chou, M. M., and Blenis, J. (1996) Cell 85, 573-583[Medline] [Order article via Infotrieve]
  34. Lenormand, P., McMahon, M., and Pouyssegur, J. (1996) J. Biol. Chem. 271, 15762-15768[Abstract/Free Full Text]
  35. Tudan, C., Jackson, J. K., Charlton, L., Pelech, S. L., Sahl, B., and Burt, H. M. (1998) Biochem. J. 331, 531-537[Medline] [Order article via Infotrieve]
  36. Seva, C., Kowalski-Chauvel, A., Daulhac, L., Barthez, C., Vaysse, N., and Pradayrol, L. (1997) Biochem. Biophys. Res. Commun. 238, 202-206[CrossRef][Medline] [Order article via Infotrieve]
  37. Kilgour, E., Gout, I., and Anderson, N. G. (1996) Biochem. J. 315, 517-522[Medline] [Order article via Infotrieve]
  38. Burkhardt, A. L., Brunswick, M., Bolen, J. B., and Mond, J. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7410-7414[Abstract]
  39. Cheng, A. M., Rowley, B., Pao, W., Hayday, A., Bolen, J., and Pawson, T. (1995) Nature 378, 303-306[CrossRef][Medline] [Order article via Infotrieve]
  40. Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I., Sparkes, R. S., Kubagawa, H., Mohandas, T., Quan, S., Belmont, J. W., Cooper, M. D., Conley, M. E., and Witte, O. N. (1993) Cell 72, 279-290[Medline] [Order article via Infotrieve]
  41. Yamanashi, Y., Kakiuchi, T., Mizuguchi, J., Yamamoto, T., and Toyoshima, K. (1991) Science 251, 192-194[Medline] [Order article via Infotrieve]
  42. Chan, V. W.-F., Meng, F., Soriano, P., DeFranco, A. L., and Lowell, C. A. (1997) Immunity 7, 69-81[Medline] [Order article via Infotrieve]
  43. Takata, M., Sabe, H., Hata, A., Inazu, T., Homma, Y., Nukada, T., Yamamura, H., and Kurosaki, T. (1994) EMBO J. 13, 1341-1349[Abstract]
  44. Sillman, A. L., and Monroe, J. G. (1996) J. Biol. Chem. 270, 11806-11811[Abstract/Free Full Text]
  45. Mishell, B. B., and Shiigi, S. M. (1980) Selected Methods in Cellular Immunology, W. H. Freeman & Co., San Francisco, CA
  46. von Manteuffel, S. R., Dennis, P. B., Pullen, N., Gingras, A. C., Sonenberg, N., and Thomas, C. (1997) Mol. Cell. Biol. 17, 5426-5436[Abstract]
  47. Chang, P. Y., Le Marchand-Brustel, Y., Cheatham, L. A., and Moller, D. E. (1995) J. Biol. Chem. 270, 29928-29935[Abstract/Free Full Text]
  48. Chang, Y. W., and Traugh, J. A. (1997) J. Biol. Chem. 272, 28252-28257[Abstract/Free Full Text]
  49. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., and Blenis, J. (1994) Nature 370, 71-75[CrossRef][Medline] [Order article via Infotrieve]
  50. Pearson, R. B., and Thomas, G. (1995) Prog. Cell Cycle Res. 1, 21-32[Medline] [Order article via Infotrieve]
  51. Kuo, C. J., Chung, J., Fiorentino, D. F., Flanagan, W. M., Blenis, J., and Crabtree, G. R. (1992) Nature 358, 70-73[CrossRef][Medline] [Order article via Infotrieve]
  52. Han, J. W., Pearson, R. B., Dennis, P. B., and Thomas, G. (1995) J. Biol. Chem. 270, 21396-21406[Abstract/Free Full Text]
  53. Pearson, R. B., Dennis, P. B., Han, J. W., Williamson, N. A., Kozma, S. C., Wettenhall, R. E., and Thomas, G. (1995) EMBO J. 14, 5279-5287[Abstract]
  54. Terada, N., Takase, K., Papst, P., Nairn, A. C., and Gelfand, E. W. (1995) J. Immunol. 155, 3418-3426[Abstract]
  55. Weng, Q.-P., Andrabi, K., Klippel, A., Kozlowski, M. T., Williams, L. T., and Avruch, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5744-5748[Abstract]
  56. Gschwendt, M., Kittstein, W., and Marks, F. (1991) Trends Biochem. Sci. 16, 167-169[CrossRef][Medline] [Order article via Infotrieve]
  57. Lu, Z., Liu, D., Hornia, A., Devonish, W., Pagano, M., and Foster, D. A. (1998) Mol. Cell. Biol. 18, 839-845[Abstract/Free Full Text]
  58. Fulcher, D. A., and Basten, A. (1997) Int. Rev. Immunol. 15, 33-52[Medline] [Order article via Infotrieve]
  59. Fulcher, D. A., Lyons, A. B., Korn, S. L., Cook, M. C., Koleda, C., Parish, C., Fazekas de St. Groth, B., and Basten, A. (1996) J. Exp. Med. 183, 2313-2328[Abstract]
  60. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911[Abstract]
  61. Weng, Q. P., Andrabi, K., Kozlowski, M. T., Grove, J. R., and Avruch, J. (1995) Mol. Cell. Biol. 15, 2333-2340[Abstract]
  62. Mahalingam, M., and Templeton, D. J. (1996) Mol. Cell. Biol. 16, 405-413[Abstract]
  63. Bjorbaek, C., Zhao, Y., and Moller, D. E. (1995) J. Biol. Chem. 270, 18848-18852[Abstract/Free Full Text]
  64. Seger, R., Biener, Y., Feinstein, R., Hanoch, T., Gazit, A., and Zick, Y. (1995) J. Biol. Chem. 270, 28325-28330[Abstract/Free Full Text]
  65. Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., and Thomas, G. (1998) Science 279, 707-710[Abstract/Free Full Text]
  66. Pullen, N., and Thomas, G. (1997) FEBS Lett. 410, 78-82[CrossRef][Medline] [Order article via Infotrieve]
  67. Dennis, P. B., Pullen, N., Kozma, S. C., and Thomas, G. (1996) Mol. Cell. Biol. 16, 6242-6262[Abstract]
  68. Cheatham, L., Monfar, M., Chou, M. M., and Blenis, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11696-700[Abstract]
  69. McIlroy, J., Chen, D., Wjasow, C., Michaeli, T., and Backer, J. M. (1997) Mol. Cell. Biol. 17, 248-255[Abstract]
  70. Reif, K., Burgering, B. M., and Cantrell, D. A. (1997) J. Biol. Chem. 272, 14426-14433[Abstract/Free Full Text]
  71. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., and Cohen, P. (1997) Curr. Biol. 7, 261-269[Medline] [Order article via Infotrieve]
  72. Katsuta, H., Tsuji, S., Niho, Y., Kurosaki, T., and Kitamura, D. (1998) J. Immunol. 160, 1547-1551[Abstract/Free Full Text]
  73. Thomas, G., and Hall, M. N. (1997) Curr. Opin. Cell Biol. 9, 782-787[CrossRef][Medline] [Order article via Infotrieve]
  74. Dumont, F. J., and Su, Q. (1996) Life Sci. 58, 373-395[CrossRef][Medline] [Order article via Infotrieve]
  75. Kato, J.-Y, Matsuoka, M., Polyak, K., Massague, J., and Sherr, C. J. (1994) Cell 79, 487-496[Medline] [Order article via Infotrieve]
  76. Healy, J. I., Dolmetsch, R. E., Timmerman, L. A., Cyster, J. G., Thomas, M. L., Crabtree, G. R., Lewis, R. S., and Goodnow, C. C. (1997) Immunity 6, 419-428[Medline] [Order article via Infotrieve]
  77. Turner, M., Mee, P. J., Costello, P. S., Williams, O., Price, A. A., Duddy, L. P., Furlong, M. T., Geahlen, R. L., and Tybulewicz, V. L. J. (1995) Nature 378, 298-302[CrossRef][Medline] [Order article via Infotrieve]
  78. Goodnow, C. C., Crosbie, J., Adelstein, S., Lavoie, T. B., Smith-Gill, S. J., Brink, R. A., Pritchard-Briscoe, H., Wotherspoon, J. S., Loblay, R. H., Raphael, K, Trent, R. J., and Basten, A. (1988) Nature 334, 676-682[CrossRef][Medline] [Order article via Infotrieve]
  79. Noorchashm, H., Bui, A., Li, H.-L., Eaton, A., Mandik-Nayak, L., Sokol, C., Puré, E., and Erikson, J. A. (1999) Int. Immunol., in press


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.